Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

June 30, December 31, 2009 2008 (unaudited) Assets Current assets: Cash and cash equivalents $105,353,616 $47,627,246 Restricted cash 1,847,848 2,195,696 Prepaid expenses and other current assets 1,733,399 219,674 Total current assets 108,934,863 50,042,616 Property and equipment, net 5,447,615 4,477,020 Restricted cash 537,586 537,586 Other assets 33,554 90,792 Total assets $114,953,618 $55,148,014 Liabilities and Stockholders' Equity Current liabilities: Accounts payable 3,767,365 $4,877,854 Accrued liabilities 3,610,492 9,063,310 Current portion of long-term debt 6,377,275 7,694,173 Other current liabilities 22,048 22,048 Total current liabilities 13,777,180 21,657,385 Deferred rent 801,175 952,274 Long-term debt, less current portion and discount 3,179,199 6,098,113 Total stockholders' equity 97,196,064 26,440,242 Total liabilities and stockholders' equity $114,953,618 $55,148,014


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
3. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 GEA Niro Soavi the leader ... homogenizer, the PandaPLUS 2000, which is ideal for new ... cell disruption . This compact laboratory homogenizer is ... liquid food, food additives and ingredients as well as ...
(Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
(Date:1/22/2015)... January 22, 2015 Dr. Greg Leyer of ... annual Scripps Natural Supplements Pre-Conference seminar on probiotics in San ... an annual continuing education conference for health care professionals. This ... the topic of probiotics in health. Dr. Leyer spoke about ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... HAYWARD, Calif., March 18 Kosan Biosciences,Incorporated (Nasdaq: ... of Directors has,appointed Helen S. Kim as Chief ... January 2008 as Senior Vice President and Chief,Business ... Peter Davis, PhD., Kosan,s Chairman of the ...
... 18 Three biotech CEOs and,the president of ... honored,today by the Greater Baltimore Committee as winners ... of the 2008 Greater Baltimore Region Bioscience Awards ... Timothy E. Askew, President & CEO, CSA,Medical, Inc. ...
... Successfully Hit Primary End Point of Preventing ... Superiority over the Market Leader, VANCOUVER, ... ANPI , TSX: ANP), a global ... that the clinical data from its 960,patient ...
Cached Biology Technology:Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 2Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 3Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 4Three CEOs and University President Named Winners of Greater Baltimore Committee's 2008 Baltimore Region Bioscience Awards 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 3960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 4960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 5960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 6960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 7
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)...  HITLAB SM announced today its completion of a ... to current U.S. Food and Drug Administration (FDA) regulations. ... and smart phone application trials utilizing the highest principles ... is determined to improve global healthcare access, quality, and ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... -- The key to understanding how future hurricanes and sea ... forests lurks below the surface, according to a new model ... mangroves that line the coasts lie hardwood hammocks that are ... University of Miami (UM) Ecologist Donald L. DeAngelis, who is ...
... dinner on R.V. Calypso while anchored on the lee side ... that he suspected humans were having a negative impact on ... the lush coral reefs of the Caribbean and Sinai Peninsulafound ... But Cousteau was right. During the following three-plus decades, Dustan, ...
... Location matters for birds on the hunt for caterpillars, according ... that chickadees and others zero in on the type of ... Unfortunately for caterpillars, munching on tree leaves that are ... becoming food. Study results, published online this week in ...
Cached Biology News:Living on the edge: An innovative model of mangrove-hammock boundaries in Florida 2Detecting detrimental change in coral reefs 2Detecting detrimental change in coral reefs 3For the birds 2
... ,Schistosomal glutathione-S-transferase (GST) is commonly used ... in E. coli (1). The GSTTag sequence ... and in some cases the solubility of ... soluble, properly folded form, GSTTag fusion proteins ...
... is from the C-terminal end of the mouse retinoic acid receptor beta ... to 448 of RAR*. The sequence of PEP-005 is (amino to ... P - S - S - V - E - N - ... P - L - L - Q (The N-terminal cysteine has ...
... LabLinx is the next step in ... modular, expandable track system that delivers labware ... up to 10 times the throughput of ... to setup a variety of configurations to ...
... potential applications for the use of small ... expression via the RNA interference,(RNAi) pathway have ... molecular biology fields. siRNA for experimental use ... enzymatically, and then transfected into the target ...
Biology Products: